An innovative PROstate cancer Screening Test based on the MCM5 ELISA Test (iPROSTMET)

在英国，每年有47,000名男性被诊断患有前列腺癌。目前，诊断需要进行侵入性活检。这对病人来说是痛苦的，对NHS来说是负担，并且有需要进一步治疗的感染风险。Arquer有一个简单的测试，针对膀胱癌进行了优化，能够检测尿液中的癌细胞。由于前列腺肿瘤会将癌细胞转移到尿液和精液中，Arquer打算将该测试用于前列腺癌的筛查和诊断工具。为了成功地将测试从膀胱癌调整到前列腺癌，Arquer需要执行研究，以充分了解前列腺癌的诊断途径，其中Arquer测试将适合临床途径，并确定任何可能影响测试效用或吸引力的潜在问题。然后，Arquer将解决这些问题，以便NHS可以轻松采用该测试。将开展工作以确保确定和实施测试的最佳性能参数，以便在这些研究之后进行完整临床试验的设计。最终的产品将是一种无需活检就能准确诊断前列腺癌的测试，使患者和临床医生都受益，同时为NHS节省大量成本。

Every year 47,000 men are diagnosed with prostate cancer in the UK. Currently, diagnosis requires an invasive biopsy to be taken. This is painful for the patient, burdomesome to the NHS and carries the risk of infection requiring further treatment. Arquer have a simple test, optimised for bladder cancer, capable of detecting cancerous cells in urine. As prostate tumours shed cancerous cells into urine and semen, Arquer intend to adapt the test for use as a screening and diagnostic tool for prostate cancer. In order to successfully adapt the test from bladder to prostate cancer, Arquer need to execute studies to fully understand the pathways for prostate cancer diagnosis, where the Arquer test would fit in to the clinical pathway and identify any potential issues which may affect utility or attractiveness of the test. Arquer will then address these issues so that the test can be easily adopted by the NHS. Work will be carried out to ensure that the optimal performance parameters for the test are identified and implemented, allowing the design of a full clinical trial to be carried out following these studies. The final product will be a test which can accurately diagnose prostate cancer without the need for biopsy, benefiting patients and clinicians alike, whilst simultaneously providing large cost savings to the NHS.